Cure My Disease

Don't miss your cure!

 Log in / Sign up

Weekly pill cocktail aims to tame resistant blood cancers

NCT ID NCT07710534

Not yet recruiting Disease control Sponsor: Virginia Commonwealth University Source: ClinicalTrials.gov ↗

First seen Jul 17, 2026 · Last updated Jul 17, 2026

Summary

This phase 2 trial tests whether a once-weekly oral combination of decitabine-cedazuridine and venetoclax is safer and as effective as standard therapy for people with relapsed or refractory acute myeloid leukemia, high-risk myelodysplastic syndrome, or high-risk myeloproliferative neoplasms. Participants are randomly assigned to receive either the new weekly regimen or the standard azacitidine-plus-venetoclax regimen. The study compares side effects and treatment-related complications between the two groups.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
a weekly oral combination of decitabine-cedazuridine and venetoclax
What this could lead to
If successful, this weekly oral regimen could offer a more convenient and less toxic treatment option for people with hard-to-treat blood cancers.
What could go wrong
This is an early phase 2 trial with only 40 participants, so results may not apply broadly. The combination may still cause serious side effects like low blood counts and infections.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HIGH RISK MYELODYSPLASTIC SYNDROME are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute myeloid leukemia myelodysplastic syndrome myeloproliferative neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HIGH RISK MYELODYSPLASTIC SYNDROME HIGH RISK MYELOPROLIFERATIVE NEOPLASMS RELAPSED / REFRACTORY AML

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Virginia Commonwealth University

    Richmond, Virginia, 23298, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

More trials for these conditions

Other studies related to the condition(s) this trial covers.